nodes	percent_of_prediction	percent_of_DWPC	metapath
Dasatinib—CYP1A1—polycystic ovary syndrome	0.282	1	CbGaD
Dasatinib—Nail disorder—Metformin—polycystic ovary syndrome	0.00255	0.0523	CcSEcCtD
Dasatinib—Contusion—Metformin—polycystic ovary syndrome	0.0019	0.0389	CcSEcCtD
Dasatinib—Neuropathy—Metformin—polycystic ovary syndrome	0.00155	0.0319	CcSEcCtD
Dasatinib—Breast disorder—Metformin—polycystic ovary syndrome	0.00109	0.0223	CcSEcCtD
Dasatinib—Abdominal distension—Metformin—polycystic ovary syndrome	0.00104	0.0214	CcSEcCtD
Dasatinib—Pancreatitis—Metformin—polycystic ovary syndrome	0.00102	0.0209	CcSEcCtD
Dasatinib—Angina pectoris—Metformin—polycystic ovary syndrome	0.00101	0.0207	CcSEcCtD
Dasatinib—Neutropenia—Metformin—polycystic ovary syndrome	0.00097	0.0199	CcSEcCtD
Dasatinib—Upper respiratory tract infection—Metformin—polycystic ovary syndrome	0.000964	0.0198	CcSEcCtD
Dasatinib—Infestation NOS—Metformin—polycystic ovary syndrome	0.000925	0.019	CcSEcCtD
Dasatinib—Infestation—Metformin—polycystic ovary syndrome	0.000925	0.019	CcSEcCtD
Dasatinib—Neuropathy peripheral—Metformin—polycystic ovary syndrome	0.000907	0.0186	CcSEcCtD
Dasatinib—FMO3—adrenal cortex—polycystic ovary syndrome	0.000903	0.00321	CbGeAlD
Dasatinib—HCK—adipose tissue—polycystic ovary syndrome	0.000901	0.00321	CbGeAlD
Dasatinib—BTK—female gonad—polycystic ovary syndrome	0.000899	0.0032	CbGeAlD
Dasatinib—ABL2—pituitary gland—polycystic ovary syndrome	0.000899	0.0032	CbGeAlD
Dasatinib—ABL2—adipose tissue—polycystic ovary syndrome	0.000895	0.00319	CbGeAlD
Dasatinib—BTK—vagina—polycystic ovary syndrome	0.000894	0.00318	CbGeAlD
Dasatinib—TESK1—adrenal gland—polycystic ovary syndrome	0.000894	0.00318	CbGeAlD
Dasatinib—CYP3A4—urine—polycystic ovary syndrome	0.00089	0.00317	CbGeAlD
Dasatinib—EPHB4—adrenal cortex—polycystic ovary syndrome	0.00089	0.00317	CbGeAlD
Dasatinib—TNK2—female gonad—polycystic ovary syndrome	0.000886	0.00315	CbGeAlD
Dasatinib—EPHB3—adrenal gland—polycystic ovary syndrome	0.00088	0.00313	CbGeAlD
Dasatinib—STK36—adrenal gland—polycystic ovary syndrome	0.00088	0.00313	CbGeAlD
Dasatinib—ZAK—endocrine gland—polycystic ovary syndrome	0.000877	0.00312	CbGeAlD
Dasatinib—Hepatobiliary disease—Metformin—polycystic ovary syndrome	0.000875	0.018	CcSEcCtD
Dasatinib—EPHA2—adrenal cortex—polycystic ovary syndrome	0.000873	0.00311	CbGeAlD
Dasatinib—EPHA5—endocrine gland—polycystic ovary syndrome	0.000858	0.00305	CbGeAlD
Dasatinib—LYN—endocrine gland—polycystic ovary syndrome	0.000854	0.00304	CbGeAlD
Dasatinib—MAP3K3—adrenal cortex—polycystic ovary syndrome	0.000851	0.00303	CbGeAlD
Dasatinib—RIPK2—pituitary gland—polycystic ovary syndrome	0.000851	0.00303	CbGeAlD
Dasatinib—LIMK2—adrenal gland—polycystic ovary syndrome	0.00085	0.00303	CbGeAlD
Dasatinib—RIPK2—adipose tissue—polycystic ovary syndrome	0.000847	0.00302	CbGeAlD
Dasatinib—SIK1—uterus—polycystic ovary syndrome	0.000846	0.00301	CbGeAlD
Dasatinib—BMPR1B—endocrine gland—polycystic ovary syndrome	0.000841	0.00299	CbGeAlD
Dasatinib—EPHA4—uterus—polycystic ovary syndrome	0.000837	0.00298	CbGeAlD
Dasatinib—FGR—endometrium—polycystic ovary syndrome	0.000835	0.00297	CbGeAlD
Dasatinib—TESK1—female gonad—polycystic ovary syndrome	0.000833	0.00297	CbGeAlD
Dasatinib—SIK1—pituitary gland—polycystic ovary syndrome	0.000831	0.00296	CbGeAlD
Dasatinib—Hepatitis—Metformin—polycystic ovary syndrome	0.000831	0.017	CcSEcCtD
Dasatinib—ERBB3—uterus—polycystic ovary syndrome	0.000829	0.00295	CbGeAlD
Dasatinib—CSF1R—embryo—polycystic ovary syndrome	0.000829	0.00295	CbGeAlD
Dasatinib—TESK1—vagina—polycystic ovary syndrome	0.000828	0.00295	CbGeAlD
Dasatinib—SIK1—adipose tissue—polycystic ovary syndrome	0.000827	0.00294	CbGeAlD
Dasatinib—TNK2—endocrine gland—polycystic ovary syndrome	0.000824	0.00293	CbGeAlD
Dasatinib—STK35—adrenal gland—polycystic ovary syndrome	0.000824	0.00293	CbGeAlD
Dasatinib—EPHA4—pituitary gland—polycystic ovary syndrome	0.000822	0.00293	CbGeAlD
Dasatinib—MAP3K2—uterus—polycystic ovary syndrome	0.000821	0.00292	CbGeAlD
Dasatinib—STK36—female gonad—polycystic ovary syndrome	0.00082	0.00292	CbGeAlD
Dasatinib—EPHB3—female gonad—polycystic ovary syndrome	0.00082	0.00292	CbGeAlD
Dasatinib—EPHA4—adipose tissue—polycystic ovary syndrome	0.000819	0.00291	CbGeAlD
Dasatinib—CSK—adrenal gland—polycystic ovary syndrome	0.000819	0.00291	CbGeAlD
Dasatinib—Oedema peripheral—Metformin—polycystic ovary syndrome	0.000818	0.0168	CcSEcCtD
Dasatinib—Connective tissue disorder—Metformin—polycystic ovary syndrome	0.000816	0.0168	CcSEcCtD
Dasatinib—EPHB3—vagina—polycystic ovary syndrome	0.000815	0.0029	CbGeAlD
Dasatinib—STK36—vagina—polycystic ovary syndrome	0.000815	0.0029	CbGeAlD
Dasatinib—ERBB3—adipose tissue—polycystic ovary syndrome	0.000811	0.00289	CbGeAlD
Dasatinib—HCK—adrenal gland—polycystic ovary syndrome	0.000808	0.00288	CbGeAlD
Dasatinib—ABL2—adrenal gland—polycystic ovary syndrome	0.000803	0.00286	CbGeAlD
Dasatinib—MAP3K2—adipose tissue—polycystic ovary syndrome	0.000803	0.00286	CbGeAlD
Dasatinib—EPHB4—endometrium—polycystic ovary syndrome	0.000794	0.00283	CbGeAlD
Dasatinib—LIMK2—female gonad—polycystic ovary syndrome	0.000793	0.00282	CbGeAlD
Dasatinib—JAK2—endometrium—polycystic ovary syndrome	0.000789	0.00281	CbGeAlD
Dasatinib—LIMK2—vagina—polycystic ovary syndrome	0.000788	0.0028	CbGeAlD
Dasatinib—YES1—adrenal cortex—polycystic ovary syndrome	0.000786	0.0028	CbGeAlD
Dasatinib—EPHA2—endometrium—polycystic ovary syndrome	0.000779	0.00277	CbGeAlD
Dasatinib—FYN—endometrium—polycystic ovary syndrome	0.000778	0.00277	CbGeAlD
Dasatinib—Eye disorder—Metformin—polycystic ovary syndrome	0.000776	0.0159	CcSEcCtD
Dasatinib—TESK1—endocrine gland—polycystic ovary syndrome	0.000775	0.00276	CbGeAlD
Dasatinib—MAPK14—uterus—polycystic ovary syndrome	0.000772	0.00275	CbGeAlD
Dasatinib—Cardiac disorder—Metformin—polycystic ovary syndrome	0.000771	0.0158	CcSEcCtD
Dasatinib—Flushing—Metformin—polycystic ovary syndrome	0.000771	0.0158	CcSEcCtD
Dasatinib—LCK—uterus—polycystic ovary syndrome	0.000769	0.00274	CbGeAlD
Dasatinib—STK35—female gonad—polycystic ovary syndrome	0.000769	0.00274	CbGeAlD
Dasatinib—STK35—vagina—polycystic ovary syndrome	0.000764	0.00272	CbGeAlD
Dasatinib—CSK—female gonad—polycystic ovary syndrome	0.000763	0.00272	CbGeAlD
Dasatinib—STK36—endocrine gland—polycystic ovary syndrome	0.000763	0.00271	CbGeAlD
Dasatinib—MAP3K3—endometrium—polycystic ovary syndrome	0.00076	0.00271	CbGeAlD
Dasatinib—MAP4K5—endometrium—polycystic ovary syndrome	0.00076	0.00271	CbGeAlD
Dasatinib—RIPK2—adrenal gland—polycystic ovary syndrome	0.00076	0.0027	CbGeAlD
Dasatinib—CSK—vagina—polycystic ovary syndrome	0.000759	0.0027	CbGeAlD
Dasatinib—MAPK14—pituitary gland—polycystic ovary syndrome	0.000758	0.0027	CbGeAlD
Dasatinib—FGR—pituitary gland—polycystic ovary syndrome	0.000755	0.00269	CbGeAlD
Dasatinib—MAPK14—adipose tissue—polycystic ovary syndrome	0.000755	0.00269	CbGeAlD
Dasatinib—HCK—female gonad—polycystic ovary syndrome	0.000754	0.00268	CbGeAlD
Dasatinib—Angiopathy—Metformin—polycystic ovary syndrome	0.000754	0.0155	CcSEcCtD
Dasatinib—KIT—embryo—polycystic ovary syndrome	0.000752	0.00268	CbGeAlD
Dasatinib—FGR—adipose tissue—polycystic ovary syndrome	0.000752	0.00268	CbGeAlD
Dasatinib—LCK—adipose tissue—polycystic ovary syndrome	0.000752	0.00268	CbGeAlD
Dasatinib—Immune system disorder—Metformin—polycystic ovary syndrome	0.00075	0.0154	CcSEcCtD
Dasatinib—HCK—vagina—polycystic ovary syndrome	0.000749	0.00267	CbGeAlD
Dasatinib—ABL2—female gonad—polycystic ovary syndrome	0.000749	0.00267	CbGeAlD
Dasatinib—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.000749	0.0154	CcSEcCtD
Dasatinib—Chills—Metformin—polycystic ovary syndrome	0.000745	0.0153	CcSEcCtD
Dasatinib—ABL2—vagina—polycystic ovary syndrome	0.000744	0.00265	CbGeAlD
Dasatinib—SIK1—adrenal gland—polycystic ovary syndrome	0.000742	0.00264	CbGeAlD
Dasatinib—LIMK2—endocrine gland—polycystic ovary syndrome	0.000737	0.00262	CbGeAlD
Dasatinib—PDGFRB—embryo—polycystic ovary syndrome	0.000735	0.00262	CbGeAlD
Dasatinib—EPHA4—adrenal gland—polycystic ovary syndrome	0.000735	0.00261	CbGeAlD
Dasatinib—EPHB4—uterus—polycystic ovary syndrome	0.000732	0.00261	CbGeAlD
Dasatinib—FMO3—pituitary gland—polycystic ovary syndrome	0.000729	0.0026	CbGeAlD
Dasatinib—EPHB6—endometrium—polycystic ovary syndrome	0.000727	0.00259	CbGeAlD
Dasatinib—FMO3—adipose tissue—polycystic ovary syndrome	0.000726	0.00259	CbGeAlD
Dasatinib—Malnutrition—Metformin—polycystic ovary syndrome	0.000723	0.0148	CcSEcCtD
Dasatinib—Erythema—Metformin—polycystic ovary syndrome	0.000723	0.0148	CcSEcCtD
Dasatinib—MAP3K2—adrenal gland—polycystic ovary syndrome	0.00072	0.00256	CbGeAlD
Dasatinib—EPHB4—pituitary gland—polycystic ovary syndrome	0.000719	0.00256	CbGeAlD
Dasatinib—FYN—uterus—polycystic ovary syndrome	0.000717	0.00255	CbGeAlD
Dasatinib—EPHB4—adipose tissue—polycystic ovary syndrome	0.000716	0.00255	CbGeAlD
Dasatinib—STK35—endocrine gland—polycystic ovary syndrome	0.000715	0.00254	CbGeAlD
Dasatinib—JAK2—pituitary gland—polycystic ovary syndrome	0.000714	0.00254	CbGeAlD
Dasatinib—JAK2—adipose tissue—polycystic ovary syndrome	0.000711	0.00253	CbGeAlD
Dasatinib—CSK—endocrine gland—polycystic ovary syndrome	0.00071	0.00253	CbGeAlD
Dasatinib—RIPK2—female gonad—polycystic ovary syndrome	0.000709	0.00252	CbGeAlD
Dasatinib—Dysgeusia—Metformin—polycystic ovary syndrome	0.000708	0.0145	CcSEcCtD
Dasatinib—EPHA2—pituitary gland—polycystic ovary syndrome	0.000705	0.00251	CbGeAlD
Dasatinib—RIPK2—vagina—polycystic ovary syndrome	0.000704	0.00251	CbGeAlD
Dasatinib—FYN—pituitary gland—polycystic ovary syndrome	0.000704	0.00251	CbGeAlD
Dasatinib—EPHA2—adipose tissue—polycystic ovary syndrome	0.000702	0.0025	CbGeAlD
Dasatinib—YES1—endometrium—polycystic ovary syndrome	0.000702	0.0025	CbGeAlD
Dasatinib—FYN—adipose tissue—polycystic ovary syndrome	0.000701	0.0025	CbGeAlD
Dasatinib—HCK—endocrine gland—polycystic ovary syndrome	0.000701	0.00249	CbGeAlD
Dasatinib—MAP4K5—uterus—polycystic ovary syndrome	0.000701	0.00249	CbGeAlD
Dasatinib—MAP2K5—adrenal cortex—polycystic ovary syndrome	0.000696	0.00248	CbGeAlD
Dasatinib—Muscle spasms—Metformin—polycystic ovary syndrome	0.000695	0.0143	CcSEcCtD
Dasatinib—SIK1—female gonad—polycystic ovary syndrome	0.000692	0.00246	CbGeAlD
Dasatinib—MAP4K5—pituitary gland—polycystic ovary syndrome	0.000688	0.00245	CbGeAlD
Dasatinib—MAP3K3—pituitary gland—polycystic ovary syndrome	0.000688	0.00245	CbGeAlD
Dasatinib—MAP3K3—adipose tissue—polycystic ovary syndrome	0.000685	0.00244	CbGeAlD
Dasatinib—MAP4K5—adipose tissue—polycystic ovary syndrome	0.000685	0.00244	CbGeAlD
Dasatinib—EPHA4—female gonad—polycystic ovary syndrome	0.000685	0.00244	CbGeAlD
Dasatinib—Vision blurred—Metformin—polycystic ovary syndrome	0.000681	0.014	CcSEcCtD
Dasatinib—EPHA4—vagina—polycystic ovary syndrome	0.000681	0.00242	CbGeAlD
Dasatinib—CSF1R—adrenal cortex—polycystic ovary syndrome	0.000679	0.00242	CbGeAlD
Dasatinib—ERBB3—female gonad—polycystic ovary syndrome	0.000678	0.00241	CbGeAlD
Dasatinib—Tremor—Metformin—polycystic ovary syndrome	0.000677	0.0139	CcSEcCtD
Dasatinib—MAPK14—adrenal gland—polycystic ovary syndrome	0.000677	0.00241	CbGeAlD
Dasatinib—LCK—adrenal gland—polycystic ovary syndrome	0.000675	0.0024	CbGeAlD
Dasatinib—FGR—adrenal gland—polycystic ovary syndrome	0.000675	0.0024	CbGeAlD
Dasatinib—MAP3K2—female gonad—polycystic ovary syndrome	0.000672	0.00239	CbGeAlD
Dasatinib—Ill-defined disorder—Metformin—polycystic ovary syndrome	0.000671	0.0138	CcSEcCtD
Dasatinib—RIPK2—endocrine gland—polycystic ovary syndrome	0.000659	0.00235	CbGeAlD
Dasatinib—EPHB6—pituitary gland—polycystic ovary syndrome	0.000657	0.00234	CbGeAlD
Dasatinib—ABL1—embryo—polycystic ovary syndrome	0.000655	0.00233	CbGeAlD
Dasatinib—EPHB6—adipose tissue—polycystic ovary syndrome	0.000655	0.00233	CbGeAlD
Dasatinib—Malaise—Metformin—polycystic ovary syndrome	0.000652	0.0134	CcSEcCtD
Dasatinib—FMO3—adrenal gland—polycystic ovary syndrome	0.000652	0.00232	CbGeAlD
Dasatinib—Syncope—Metformin—polycystic ovary syndrome	0.000648	0.0133	CcSEcCtD
Dasatinib—YES1—uterus—polycystic ovary syndrome	0.000647	0.0023	CbGeAlD
Dasatinib—SIK1—endocrine gland—polycystic ovary syndrome	0.000644	0.00229	CbGeAlD
Dasatinib—EPHB4—adrenal gland—polycystic ovary syndrome	0.000642	0.00229	CbGeAlD
Dasatinib—Palpitations—Metformin—polycystic ovary syndrome	0.000639	0.0131	CcSEcCtD
Dasatinib—JAK2—adrenal gland—polycystic ovary syndrome	0.000638	0.00227	CbGeAlD
Dasatinib—EPHA4—endocrine gland—polycystic ovary syndrome	0.000637	0.00227	CbGeAlD
Dasatinib—Loss of consciousness—Metformin—polycystic ovary syndrome	0.000636	0.013	CcSEcCtD
Dasatinib—YES1—pituitary gland—polycystic ovary syndrome	0.000635	0.00226	CbGeAlD
Dasatinib—PDGFRA—uterus—polycystic ovary syndrome	0.000635	0.00226	CbGeAlD
Dasatinib—YES1—adipose tissue—polycystic ovary syndrome	0.000633	0.00225	CbGeAlD
Dasatinib—MAPK14—female gonad—polycystic ovary syndrome	0.000632	0.00225	CbGeAlD
Dasatinib—ERBB3—endocrine gland—polycystic ovary syndrome	0.000631	0.00225	CbGeAlD
Dasatinib—EPHA2—adrenal gland—polycystic ovary syndrome	0.00063	0.00224	CbGeAlD
Dasatinib—FGR—female gonad—polycystic ovary syndrome	0.000629	0.00224	CbGeAlD
Dasatinib—LCK—female gonad—polycystic ovary syndrome	0.000629	0.00224	CbGeAlD
Dasatinib—FYN—adrenal gland—polycystic ovary syndrome	0.000629	0.00224	CbGeAlD
Dasatinib—MAPK14—vagina—polycystic ovary syndrome	0.000628	0.00223	CbGeAlD
Dasatinib—FGR—vagina—polycystic ovary syndrome	0.000625	0.00223	CbGeAlD
Dasatinib—LCK—vagina—polycystic ovary syndrome	0.000625	0.00223	CbGeAlD
Dasatinib—MAP3K2—endocrine gland—polycystic ovary syndrome	0.000625	0.00222	CbGeAlD
Dasatinib—Hypertension—Metformin—polycystic ovary syndrome	0.000624	0.0128	CcSEcCtD
Dasatinib—MAP2K5—endometrium—polycystic ovary syndrome	0.000621	0.00221	CbGeAlD
Dasatinib—PDGFRA—adipose tissue—polycystic ovary syndrome	0.000621	0.00221	CbGeAlD
Dasatinib—Myalgia—Metformin—polycystic ovary syndrome	0.000616	0.0126	CcSEcCtD
Dasatinib—Chest pain—Metformin—polycystic ovary syndrome	0.000616	0.0126	CcSEcCtD
Dasatinib—MAP4K5—adrenal gland—polycystic ovary syndrome	0.000615	0.00219	CbGeAlD
Dasatinib—MAP3K3—adrenal gland—polycystic ovary syndrome	0.000615	0.00219	CbGeAlD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.000611	0.0125	CcSEcCtD
Dasatinib—SRC—adipose tissue—polycystic ovary syndrome	0.000609	0.00217	CbGeAlD
Dasatinib—Discomfort—Metformin—polycystic ovary syndrome	0.000608	0.0125	CcSEcCtD
Dasatinib—CSF1R—endometrium—polycystic ovary syndrome	0.000606	0.00216	CbGeAlD
Dasatinib—FMO3—vagina—polycystic ovary syndrome	0.000604	0.00215	CbGeAlD
Dasatinib—PDGFRB—adrenal cortex—polycystic ovary syndrome	0.000602	0.00214	CbGeAlD
Dasatinib—EPHB4—female gonad—polycystic ovary syndrome	0.000599	0.00213	CbGeAlD
Dasatinib—EPHB4—vagina—polycystic ovary syndrome	0.000595	0.00212	CbGeAlD
Dasatinib—JAK2—female gonad—polycystic ovary syndrome	0.000595	0.00212	CbGeAlD
Dasatinib—JAK2—vagina—polycystic ovary syndrome	0.000591	0.0021	CbGeAlD
Dasatinib—Oedema—Metformin—polycystic ovary syndrome	0.00059	0.0121	CcSEcCtD
Dasatinib—MAPK14—endocrine gland—polycystic ovary syndrome	0.000587	0.00209	CbGeAlD
Dasatinib—EPHA2—female gonad—polycystic ovary syndrome	0.000587	0.00209	CbGeAlD
Dasatinib—EPHB6—adrenal gland—polycystic ovary syndrome	0.000587	0.00209	CbGeAlD
Dasatinib—FYN—female gonad—polycystic ovary syndrome	0.000586	0.00209	CbGeAlD
Dasatinib—Infection—Metformin—polycystic ovary syndrome	0.000586	0.012	CcSEcCtD
Dasatinib—FGR—endocrine gland—polycystic ovary syndrome	0.000585	0.00208	CbGeAlD
Dasatinib—EPHA2—vagina—polycystic ovary syndrome	0.000584	0.00208	CbGeAlD
Dasatinib—FYN—vagina—polycystic ovary syndrome	0.000583	0.00207	CbGeAlD
Dasatinib—Shock—Metformin—polycystic ovary syndrome	0.000581	0.0119	CcSEcCtD
Dasatinib—Nervous system disorder—Metformin—polycystic ovary syndrome	0.000579	0.0119	CcSEcCtD
Dasatinib—Thrombocytopenia—Metformin—polycystic ovary syndrome	0.000578	0.0119	CcSEcCtD
Dasatinib—Skin disorder—Metformin—polycystic ovary syndrome	0.000573	0.0118	CcSEcCtD
Dasatinib—MAP4K5—female gonad—polycystic ovary syndrome	0.000573	0.00204	CbGeAlD
Dasatinib—MAP3K3—female gonad—polycystic ovary syndrome	0.000573	0.00204	CbGeAlD
Dasatinib—Hyperhidrosis—Metformin—polycystic ovary syndrome	0.00057	0.0117	CcSEcCtD
Dasatinib—MAP3K3—vagina—polycystic ovary syndrome	0.00057	0.00203	CbGeAlD
Dasatinib—MAP4K5—vagina—polycystic ovary syndrome	0.00057	0.00203	CbGeAlD
Dasatinib—YES1—adrenal gland—polycystic ovary syndrome	0.000568	0.00202	CbGeAlD
Dasatinib—FMO3—endocrine gland—polycystic ovary syndrome	0.000565	0.00201	CbGeAlD
Dasatinib—Anorexia—Metformin—polycystic ovary syndrome	0.000563	0.0115	CcSEcCtD
Dasatinib—MAP2K5—pituitary gland—polycystic ovary syndrome	0.000562	0.002	CbGeAlD
Dasatinib—MAP2K5—adipose tissue—polycystic ovary syndrome	0.00056	0.00199	CbGeAlD
Dasatinib—CSF1R—uterus—polycystic ovary syndrome	0.000559	0.00199	CbGeAlD
Dasatinib—EPHB4—endocrine gland—polycystic ovary syndrome	0.000557	0.00198	CbGeAlD
Dasatinib—PDGFRA—adrenal gland—polycystic ovary syndrome	0.000557	0.00198	CbGeAlD
Dasatinib—JAK2—endocrine gland—polycystic ovary syndrome	0.000553	0.00197	CbGeAlD
Dasatinib—Hypotension—Metformin—polycystic ovary syndrome	0.000551	0.0113	CcSEcCtD
Dasatinib—KIT—endometrium—polycystic ovary syndrome	0.000551	0.00196	CbGeAlD
Dasatinib—CSF1R—pituitary gland—polycystic ovary syndrome	0.000549	0.00195	CbGeAlD
Dasatinib—EPHB6—female gonad—polycystic ovary syndrome	0.000548	0.00195	CbGeAlD
Dasatinib—CSF1R—adipose tissue—polycystic ovary syndrome	0.000546	0.00194	CbGeAlD
Dasatinib—EPHA2—endocrine gland—polycystic ovary syndrome	0.000546	0.00194	CbGeAlD
Dasatinib—SRC—adrenal gland—polycystic ovary syndrome	0.000546	0.00194	CbGeAlD
Dasatinib—FYN—endocrine gland—polycystic ovary syndrome	0.000545	0.00194	CbGeAlD
Dasatinib—EPHB6—vagina—polycystic ovary syndrome	0.000544	0.00194	CbGeAlD
Dasatinib—PDGFRB—endometrium—polycystic ovary syndrome	0.000538	0.00191	CbGeAlD
Dasatinib—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.000538	0.011	CcSEcCtD
Dasatinib—ABL1—adrenal cortex—polycystic ovary syndrome	0.000537	0.00191	CbGeAlD
Dasatinib—MAP3K3—endocrine gland—polycystic ovary syndrome	0.000533	0.0019	CbGeAlD
Dasatinib—MAP4K5—endocrine gland—polycystic ovary syndrome	0.000533	0.0019	CbGeAlD
Dasatinib—YES1—female gonad—polycystic ovary syndrome	0.000529	0.00188	CbGeAlD
Dasatinib—Dyspnoea—Metformin—polycystic ovary syndrome	0.000526	0.0108	CcSEcCtD
Dasatinib—YES1—vagina—polycystic ovary syndrome	0.000526	0.00187	CbGeAlD
Dasatinib—Somnolence—Metformin—polycystic ovary syndrome	0.000525	0.0108	CcSEcCtD
Dasatinib—Dyspepsia—Metformin—polycystic ovary syndrome	0.000519	0.0107	CcSEcCtD
Dasatinib—PDGFRA—female gonad—polycystic ovary syndrome	0.000519	0.00185	CbGeAlD
Dasatinib—PDGFRA—vagina—polycystic ovary syndrome	0.000516	0.00184	CbGeAlD
Dasatinib—Decreased appetite—Metformin—polycystic ovary syndrome	0.000513	0.0105	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.000509	0.0105	CcSEcCtD
Dasatinib—SRC—female gonad—polycystic ovary syndrome	0.000509	0.00181	CbGeAlD
Dasatinib—Fatigue—Metformin—polycystic ovary syndrome	0.000509	0.0104	CcSEcCtD
Dasatinib—KIT—uterus—polycystic ovary syndrome	0.000507	0.00181	CbGeAlD
Dasatinib—Constipation—Metformin—polycystic ovary syndrome	0.000505	0.0104	CcSEcCtD
Dasatinib—MAP2K5—adrenal gland—polycystic ovary syndrome	0.000502	0.00179	CbGeAlD
Dasatinib—KIT—pituitary gland—polycystic ovary syndrome	0.000498	0.00177	CbGeAlD
Dasatinib—KIT—adipose tissue—polycystic ovary syndrome	0.000496	0.00177	CbGeAlD
Dasatinib—PDGFRB—uterus—polycystic ovary syndrome	0.000496	0.00176	CbGeAlD
Dasatinib—YES1—endocrine gland—polycystic ovary syndrome	0.000492	0.00175	CbGeAlD
Dasatinib—CSF1R—adrenal gland—polycystic ovary syndrome	0.00049	0.00174	CbGeAlD
Dasatinib—PDGFRB—pituitary gland—polycystic ovary syndrome	0.000487	0.00173	CbGeAlD
Dasatinib—Feeling abnormal—Metformin—polycystic ovary syndrome	0.000486	0.00998	CcSEcCtD
Dasatinib—PDGFRB—adipose tissue—polycystic ovary syndrome	0.000485	0.00172	CbGeAlD
Dasatinib—PDGFRA—endocrine gland—polycystic ovary syndrome	0.000483	0.00172	CbGeAlD
Dasatinib—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.000483	0.0099	CcSEcCtD
Dasatinib—ABL1—endometrium—polycystic ovary syndrome	0.000479	0.00171	CbGeAlD
Dasatinib—SRC—endocrine gland—polycystic ovary syndrome	0.000473	0.00169	CbGeAlD
Dasatinib—Urticaria—Metformin—polycystic ovary syndrome	0.000469	0.00962	CcSEcCtD
Dasatinib—MAP2K5—female gonad—polycystic ovary syndrome	0.000468	0.00167	CbGeAlD
Dasatinib—Abdominal pain—Metformin—polycystic ovary syndrome	0.000467	0.00957	CcSEcCtD
Dasatinib—MAP2K5—vagina—polycystic ovary syndrome	0.000465	0.00166	CbGeAlD
Dasatinib—CSF1R—female gonad—polycystic ovary syndrome	0.000457	0.00163	CbGeAlD
Dasatinib—CSF1R—vagina—polycystic ovary syndrome	0.000454	0.00162	CbGeAlD
Dasatinib—KIT—adrenal gland—polycystic ovary syndrome	0.000445	0.00158	CbGeAlD
Dasatinib—ABL1—uterus—polycystic ovary syndrome	0.000442	0.00157	CbGeAlD
Dasatinib—MAP2K5—endocrine gland—polycystic ovary syndrome	0.000436	0.00155	CbGeAlD
Dasatinib—PDGFRB—adrenal gland—polycystic ovary syndrome	0.000435	0.00155	CbGeAlD
Dasatinib—ABL1—pituitary gland—polycystic ovary syndrome	0.000434	0.00154	CbGeAlD
Dasatinib—ABL1—adipose tissue—polycystic ovary syndrome	0.000432	0.00154	CbGeAlD
Dasatinib—CSF1R—endocrine gland—polycystic ovary syndrome	0.000425	0.00151	CbGeAlD
Dasatinib—Asthenia—Metformin—polycystic ovary syndrome	0.000423	0.00869	CcSEcCtD
Dasatinib—Pruritus—Metformin—polycystic ovary syndrome	0.000418	0.00857	CcSEcCtD
Dasatinib—KIT—female gonad—polycystic ovary syndrome	0.000415	0.00148	CbGeAlD
Dasatinib—KIT—vagina—polycystic ovary syndrome	0.000413	0.00147	CbGeAlD
Dasatinib—PDGFRB—female gonad—polycystic ovary syndrome	0.000405	0.00144	CbGeAlD
Dasatinib—Diarrhoea—Metformin—polycystic ovary syndrome	0.000404	0.00829	CcSEcCtD
Dasatinib—PDGFRB—vagina—polycystic ovary syndrome	0.000403	0.00143	CbGeAlD
Dasatinib—Dizziness—Metformin—polycystic ovary syndrome	0.00039	0.00801	CcSEcCtD
Dasatinib—ABL1—adrenal gland—polycystic ovary syndrome	0.000387	0.00138	CbGeAlD
Dasatinib—KIT—endocrine gland—polycystic ovary syndrome	0.000386	0.00137	CbGeAlD
Dasatinib—PDGFRB—endocrine gland—polycystic ovary syndrome	0.000377	0.00134	CbGeAlD
Dasatinib—Vomiting—Metformin—polycystic ovary syndrome	0.000375	0.0077	CcSEcCtD
Dasatinib—CYP1B1—uterus—polycystic ovary syndrome	0.000374	0.00133	CbGeAlD
Dasatinib—Rash—Metformin—polycystic ovary syndrome	0.000372	0.00764	CcSEcCtD
Dasatinib—Dermatitis—Metformin—polycystic ovary syndrome	0.000372	0.00763	CcSEcCtD
Dasatinib—Headache—Metformin—polycystic ovary syndrome	0.00037	0.00759	CcSEcCtD
Dasatinib—CYP1B1—pituitary gland—polycystic ovary syndrome	0.000367	0.00131	CbGeAlD
Dasatinib—CYP1B1—adipose tissue—polycystic ovary syndrome	0.000366	0.0013	CbGeAlD
Dasatinib—ABL1—female gonad—polycystic ovary syndrome	0.000361	0.00129	CbGeAlD
Dasatinib—ABL1—vagina—polycystic ovary syndrome	0.000359	0.00128	CbGeAlD
Dasatinib—Nausea—Metformin—polycystic ovary syndrome	0.000351	0.00719	CcSEcCtD
Dasatinib—ABCG2—adrenal cortex—polycystic ovary syndrome	0.000339	0.0012	CbGeAlD
Dasatinib—ABL1—endocrine gland—polycystic ovary syndrome	0.000336	0.0012	CbGeAlD
Dasatinib—CYP1B1—adrenal gland—polycystic ovary syndrome	0.000328	0.00117	CbGeAlD
Dasatinib—CYP1B1—female gonad—polycystic ovary syndrome	0.000306	0.00109	CbGeAlD
Dasatinib—ABCG2—endometrium—polycystic ovary syndrome	0.000302	0.00108	CbGeAlD
Dasatinib—CYP1B1—endocrine gland—polycystic ovary syndrome	0.000285	0.00101	CbGeAlD
Dasatinib—ABCG2—uterus—polycystic ovary syndrome	0.000279	0.000991	CbGeAlD
Dasatinib—ABCG2—pituitary gland—polycystic ovary syndrome	0.000274	0.000973	CbGeAlD
Dasatinib—ABCG2—adipose tissue—polycystic ovary syndrome	0.000272	0.00097	CbGeAlD
Dasatinib—CYP1A1—uterus—polycystic ovary syndrome	0.000264	0.000941	CbGeAlD
Dasatinib—CYP1A1—adipose tissue—polycystic ovary syndrome	0.000259	0.00092	CbGeAlD
Dasatinib—CYP3A5—adipose tissue—polycystic ovary syndrome	0.000253	0.0009	CbGeAlD
Dasatinib—ABCG2—adrenal gland—polycystic ovary syndrome	0.000244	0.00087	CbGeAlD
Dasatinib—ABCG2—female gonad—polycystic ovary syndrome	0.000228	0.000811	CbGeAlD
Dasatinib—ABCG2—vagina—polycystic ovary syndrome	0.000226	0.000806	CbGeAlD
Dasatinib—CYP1A1—female gonad—polycystic ovary syndrome	0.000216	0.00077	CbGeAlD
Dasatinib—CYP1A1—vagina—polycystic ovary syndrome	0.000215	0.000765	CbGeAlD
Dasatinib—CYP3A5—female gonad—polycystic ovary syndrome	0.000211	0.000753	CbGeAlD
Dasatinib—CYP3A5—vagina—polycystic ovary syndrome	0.00021	0.000748	CbGeAlD
Dasatinib—CYP1A2—endocrine gland—polycystic ovary syndrome	0.000204	0.000726	CbGeAlD
Dasatinib—ABCB1—embryo—polycystic ovary syndrome	0.000204	0.000725	CbGeAlD
Dasatinib—CYP1A1—endocrine gland—polycystic ovary syndrome	0.000201	0.000716	CbGeAlD
Dasatinib—CYP3A5—endocrine gland—polycystic ovary syndrome	0.000197	0.0007	CbGeAlD
Dasatinib—ABCB1—adrenal cortex—polycystic ovary syndrome	0.000167	0.000594	CbGeAlD
Dasatinib—ABCB1—endometrium—polycystic ovary syndrome	0.000149	0.00053	CbGeAlD
Dasatinib—CYP3A4—endocrine gland—polycystic ovary syndrome	0.000148	0.000525	CbGeAlD
Dasatinib—ABCB1—uterus—polycystic ovary syndrome	0.000137	0.000489	CbGeAlD
Dasatinib—ABCB1—pituitary gland—polycystic ovary syndrome	0.000135	0.00048	CbGeAlD
Dasatinib—ABCB1—adipose tissue—polycystic ovary syndrome	0.000134	0.000478	CbGeAlD
Dasatinib—ABCB1—adrenal gland—polycystic ovary syndrome	0.00012	0.000429	CbGeAlD
Dasatinib—ABCB1—female gonad—polycystic ovary syndrome	0.000112	0.0004	CbGeAlD
Dasatinib—ABCB1—vagina—polycystic ovary syndrome	0.000112	0.000397	CbGeAlD
Dasatinib—ABCB1—endocrine gland—polycystic ovary syndrome	0.000104	0.000372	CbGeAlD
Dasatinib—ABCG2—Metabolism—CYP1A1—polycystic ovary syndrome	4.64e-06	1.19e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—RRM2—polycystic ovary syndrome	4.62e-06	1.19e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—SRD5A1—polycystic ovary syndrome	4.56e-06	1.18e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—IRS1—polycystic ovary syndrome	4.53e-06	1.17e-05	CbGpPWpGaD
Dasatinib—MAPK14—Developmental Biology—IL6—polycystic ovary syndrome	4.51e-06	1.16e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—TH—polycystic ovary syndrome	4.5e-06	1.16e-05	CbGpPWpGaD
Dasatinib—HCK—Immune System—IL6—polycystic ovary syndrome	4.5e-06	1.16e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—NGFR—polycystic ovary syndrome	4.5e-06	1.16e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	4.49e-06	1.16e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—IRS2—polycystic ovary syndrome	4.49e-06	1.16e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—BCL2—polycystic ovary syndrome	4.48e-06	1.15e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PRL—polycystic ovary syndrome	4.46e-06	1.15e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	4.46e-06	1.15e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—YAP1—polycystic ovary syndrome	4.45e-06	1.15e-05	CbGpPWpGaD
Dasatinib—JAK2—Developmental Biology—IL6—polycystic ovary syndrome	4.45e-06	1.15e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—SERPINE1—polycystic ovary syndrome	4.44e-06	1.14e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—AKT2—polycystic ovary syndrome	4.43e-06	1.14e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—GNAS—polycystic ovary syndrome	4.43e-06	1.14e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—IRS1—polycystic ovary syndrome	4.42e-06	1.14e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—BCL2—polycystic ovary syndrome	4.42e-06	1.14e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—IRS2—polycystic ovary syndrome	4.42e-06	1.14e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—SLC2A4—polycystic ovary syndrome	4.38e-06	1.13e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—LHB—polycystic ovary syndrome	4.37e-06	1.13e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—POMC—polycystic ovary syndrome	4.36e-06	1.12e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—STAR—polycystic ovary syndrome	4.35e-06	1.12e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—INS—polycystic ovary syndrome	4.33e-06	1.12e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—IRS2—polycystic ovary syndrome	4.33e-06	1.12e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—LEP—polycystic ovary syndrome	4.33e-06	1.11e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—MTHFR—polycystic ovary syndrome	4.32e-06	1.11e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Innate Immune System—IL6—polycystic ovary syndrome	4.29e-06	1.11e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—IRS1—polycystic ovary syndrome	4.28e-06	1.1e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—NAMPT—polycystic ovary syndrome	4.28e-06	1.1e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—HSD3B2—polycystic ovary syndrome	4.27e-06	1.1e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—IRS2—polycystic ovary syndrome	4.26e-06	1.1e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—TH—polycystic ovary syndrome	4.26e-06	1.1e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—IRS1—polycystic ovary syndrome	4.24e-06	1.09e-05	CbGpPWpGaD
Dasatinib—RIPK2—Immune System—IL6—polycystic ovary syndrome	4.24e-06	1.09e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—LEP—polycystic ovary syndrome	4.24e-06	1.09e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—INS—polycystic ovary syndrome	4.24e-06	1.09e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—ADRB2—polycystic ovary syndrome	4.23e-06	1.09e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—CYP11A1—polycystic ovary syndrome	4.23e-06	1.09e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—NCOR1—polycystic ovary syndrome	4.22e-06	1.09e-05	CbGpPWpGaD
Dasatinib—LYN—Innate Immune System—IL6—polycystic ovary syndrome	4.2e-06	1.08e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—IGF1—polycystic ovary syndrome	4.19e-06	1.08e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—AKT2—polycystic ovary syndrome	4.19e-06	1.08e-05	CbGpPWpGaD
Dasatinib—ABL1—Innate Immune System—IL6—polycystic ovary syndrome	4.18e-06	1.08e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—LEP—polycystic ovary syndrome	4.17e-06	1.07e-05	CbGpPWpGaD
Dasatinib—HCK—Disease—IL6—polycystic ovary syndrome	4.15e-06	1.07e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—NRG1—polycystic ovary syndrome	4.14e-06	1.07e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—SLC2A4—polycystic ovary syndrome	4.14e-06	1.07e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—AKR1C1—polycystic ovary syndrome	4.14e-06	1.07e-05	CbGpPWpGaD
Dasatinib—FYN—Innate Immune System—IL6—polycystic ovary syndrome	4.13e-06	1.07e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—POMC—polycystic ovary syndrome	4.13e-06	1.06e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—CYP19A1—polycystic ovary syndrome	4.12e-06	1.06e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—IRS2—polycystic ovary syndrome	4.1e-06	1.06e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—INS—polycystic ovary syndrome	4.1e-06	1.06e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—AKT2—polycystic ovary syndrome	4.09e-06	1.05e-05	CbGpPWpGaD
Dasatinib—BLK—Immune System—IL6—polycystic ovary syndrome	4.08e-06	1.05e-05	CbGpPWpGaD
Dasatinib—FGR—Immune System—IL6—polycystic ovary syndrome	4.06e-06	1.05e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—IRS2—polycystic ovary syndrome	4.05e-06	1.04e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—LEP—polycystic ovary syndrome	4.02e-06	1.03e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—AKR1C3—polycystic ovary syndrome	3.99e-06	1.03e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.98e-06	1.03e-05	CbGpPWpGaD
Dasatinib—MAPK14—Innate Immune System—IL6—polycystic ovary syndrome	3.98e-06	1.03e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—IGF1—polycystic ovary syndrome	3.97e-06	1.02e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—AKT2—polycystic ovary syndrome	3.97e-06	1.02e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—LEP—polycystic ovary syndrome	3.96e-06	1.02e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.96e-06	1.02e-05	CbGpPWpGaD
Dasatinib—JAK2—Innate Immune System—IL6—polycystic ovary syndrome	3.93e-06	1.01e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—CYP17A1—polycystic ovary syndrome	3.93e-06	1.01e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—AKT2—polycystic ovary syndrome	3.93e-06	1.01e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—GNAS—polycystic ovary syndrome	3.92e-06	1.01e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—IRS1—polycystic ovary syndrome	3.92e-06	1.01e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—CYP19A1—polycystic ovary syndrome	3.89e-06	1e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—SERPINE1—polycystic ovary syndrome	3.89e-06	1e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—HMMR—polycystic ovary syndrome	3.88e-06	9.99e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—BCL2—polycystic ovary syndrome	3.87e-06	9.98e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—IRS1—polycystic ovary syndrome	3.86e-06	9.94e-06	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—PPARG—polycystic ovary syndrome	3.85e-06	9.92e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—SULT2A1—polycystic ovary syndrome	3.81e-06	9.81e-06	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—POMC—polycystic ovary syndrome	3.8e-06	9.79e-06	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—IL6—polycystic ovary syndrome	3.79e-06	9.77e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—IRS1—polycystic ovary syndrome	3.78e-06	9.74e-06	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—INS—polycystic ovary syndrome	3.78e-06	9.73e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.77e-06	9.71e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—INS—polycystic ovary syndrome	3.75e-06	9.66e-06	CbGpPWpGaD
Dasatinib—ERBB3—Immune System—IL6—polycystic ovary syndrome	3.74e-06	9.63e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—NCOR1—polycystic ovary syndrome	3.74e-06	9.63e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—IRS1—polycystic ovary syndrome	3.72e-06	9.59e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—POMC—polycystic ovary syndrome	3.72e-06	9.58e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—HSD3B1—polycystic ovary syndrome	3.7e-06	9.53e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—INS—polycystic ovary syndrome	3.7e-06	9.52e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—RRM2—polycystic ovary syndrome	3.69e-06	9.5e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—GNAS—polycystic ovary syndrome	3.68e-06	9.47e-06	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—IL6—polycystic ovary syndrome	3.67e-06	9.46e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—NRG1—polycystic ovary syndrome	3.67e-06	9.45e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—POMC—polycystic ovary syndrome	3.64e-06	9.38e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—AKT2—polycystic ovary syndrome	3.62e-06	9.34e-06	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.62e-06	9.34e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—INS—polycystic ovary syndrome	3.62e-06	9.32e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—POMC—polycystic ovary syndrome	3.58e-06	9.23e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—IRS1—polycystic ovary syndrome	3.58e-06	9.23e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—IGF1—polycystic ovary syndrome	3.58e-06	9.21e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—AKT2—polycystic ovary syndrome	3.57e-06	9.2e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—INS—polycystic ovary syndrome	3.56e-06	9.18e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—YAP1—polycystic ovary syndrome	3.56e-06	9.16e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—IRS2—polycystic ovary syndrome	3.55e-06	9.14e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—IRS1—polycystic ovary syndrome	3.54e-06	9.11e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—PPARG—polycystic ovary syndrome	3.5e-06	9.03e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—NCOR1—polycystic ovary syndrome	3.5e-06	9.03e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—IGF1—polycystic ovary syndrome	3.5e-06	9.02e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—AKT2—polycystic ovary syndrome	3.5e-06	9.01e-06	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.49e-06	9e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—GNAS—polycystic ovary syndrome	3.47e-06	8.95e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—LEP—polycystic ovary syndrome	3.47e-06	8.95e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—POMC—polycystic ovary syndrome	3.46e-06	8.9e-06	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—IL6—polycystic ovary syndrome	3.45e-06	8.89e-06	CbGpPWpGaD
Dasatinib—ERBB3—Disease—IL6—polycystic ovary syndrome	3.45e-06	8.89e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—POMC—polycystic ovary syndrome	3.45e-06	8.89e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—IGF1—polycystic ovary syndrome	3.45e-06	8.88e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—SERPINE1—polycystic ovary syndrome	3.44e-06	8.87e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—AKT2—polycystic ovary syndrome	3.44e-06	8.87e-06	CbGpPWpGaD
Dasatinib—LCK—Innate Immune System—IL6—polycystic ovary syndrome	3.44e-06	8.87e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—INS—polycystic ovary syndrome	3.44e-06	8.85e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—INS—polycystic ovary syndrome	3.43e-06	8.84e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—BCL2—polycystic ovary syndrome	3.43e-06	8.84e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—NAMPT—polycystic ovary syndrome	3.42e-06	8.8e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—POMC—polycystic ovary syndrome	3.41e-06	8.77e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—TH—polycystic ovary syndrome	3.4e-06	8.76e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	3.4e-06	8.75e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.4e-06	8.75e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—INS—polycystic ovary syndrome	3.39e-06	8.73e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—LHB—polycystic ovary syndrome	3.37e-06	8.69e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—CYP11A1—polycystic ovary syndrome	3.37e-06	8.69e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	3.35e-06	8.63e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.32e-06	8.56e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—CYP1A1—polycystic ovary syndrome	3.32e-06	8.56e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—IGF1—polycystic ovary syndrome	3.32e-06	8.55e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—AKT2—polycystic ovary syndrome	3.32e-06	8.54e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—NCOR1—polycystic ovary syndrome	3.31e-06	8.53e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—SLC2A4—polycystic ovary syndrome	3.31e-06	8.52e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—HSD3B2—polycystic ovary syndrome	3.3e-06	8.5e-06	CbGpPWpGaD
Dasatinib—YES1—Immune System—IL6—polycystic ovary syndrome	3.28e-06	8.45e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—IGF1—polycystic ovary syndrome	3.28e-06	8.44e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—AKT2—polycystic ovary syndrome	3.27e-06	8.43e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.27e-06	8.43e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—AKR1C1—polycystic ovary syndrome	3.19e-06	8.23e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—AKR1C3—polycystic ovary syndrome	3.19e-06	8.21e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.15e-06	8.12e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IRS2—polycystic ovary syndrome	3.14e-06	8.09e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—CYP17A1—polycystic ovary syndrome	3.14e-06	8.08e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.11e-06	8.01e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—CYP19A1—polycystic ovary syndrome	3.11e-06	8.01e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—IRS1—polycystic ovary syndrome	3.1e-06	7.98e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—MTHFR—polycystic ovary syndrome	3.1e-06	7.98e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—LEP—polycystic ovary syndrome	3.07e-06	7.92e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.07e-06	7.9e-06	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—IL6—polycystic ovary syndrome	3.05e-06	7.85e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—POMC—polycystic ovary syndrome	2.98e-06	7.69e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—INS—polycystic ovary syndrome	2.97e-06	7.64e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—SULT2A1—polycystic ovary syndrome	2.94e-06	7.57e-06	CbGpPWpGaD
Dasatinib—KIT—Immune System—IL6—polycystic ovary syndrome	2.93e-06	7.55e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—MTHFR—polycystic ovary syndrome	2.93e-06	7.54e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—IGF1—polycystic ovary syndrome	2.87e-06	7.39e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—AKT2—polycystic ovary syndrome	2.87e-06	7.39e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—RRM2—polycystic ovary syndrome	2.85e-06	7.33e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—GNAS—polycystic ovary syndrome	2.78e-06	7.15e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—IL6—polycystic ovary syndrome	2.77e-06	7.14e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—YAP1—polycystic ovary syndrome	2.74e-06	7.07e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IRS1—polycystic ovary syndrome	2.74e-06	7.07e-06	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—IL6—polycystic ovary syndrome	2.74e-06	7.06e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.74e-06	7.06e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.72e-06	7.02e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—TH—polycystic ovary syndrome	2.71e-06	6.99e-06	CbGpPWpGaD
Dasatinib—KIT—Disease—IL6—polycystic ovary syndrome	2.7e-06	6.97e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—NCOR1—polycystic ovary syndrome	2.64e-06	6.81e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—POMC—polycystic ovary syndrome	2.64e-06	6.8e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—SLC2A4—polycystic ovary syndrome	2.64e-06	6.8e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—NAMPT—polycystic ovary syndrome	2.64e-06	6.79e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—INS—polycystic ovary syndrome	2.63e-06	6.77e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CYP11A1—polycystic ovary syndrome	2.6e-06	6.71e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.59e-06	6.68e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—IL6—polycystic ovary syndrome	2.56e-06	6.6e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IGF1—polycystic ovary syndrome	2.54e-06	6.54e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—AKT2—polycystic ovary syndrome	2.54e-06	6.54e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PPARG—polycystic ovary syndrome	2.51e-06	6.47e-06	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—IL6—polycystic ovary syndrome	2.51e-06	6.46e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—CYP1A1—polycystic ovary syndrome	2.51e-06	6.46e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—IL6—polycystic ovary syndrome	2.51e-06	6.45e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—IL6—polycystic ovary syndrome	2.5e-06	6.44e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—CYP19A1—polycystic ovary syndrome	2.48e-06	6.39e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—POMC—polycystic ovary syndrome	2.48e-06	6.38e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—INS—polycystic ovary syndrome	2.46e-06	6.34e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—AKR1C3—polycystic ovary syndrome	2.46e-06	6.33e-06	CbGpPWpGaD
Dasatinib—LYN—Immune System—IL6—polycystic ovary syndrome	2.45e-06	6.3e-06	CbGpPWpGaD
Dasatinib—ABL1—Immune System—IL6—polycystic ovary syndrome	2.43e-06	6.27e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CYP17A1—polycystic ovary syndrome	2.42e-06	6.24e-06	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—IL6—polycystic ovary syndrome	2.42e-06	6.22e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.41e-06	6.21e-06	CbGpPWpGaD
Dasatinib—FYN—Immune System—IL6—polycystic ovary syndrome	2.41e-06	6.2e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PPARG—polycystic ovary syndrome	2.37e-06	6.11e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—POMC—polycystic ovary syndrome	2.34e-06	6.03e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—MTHFR—polycystic ovary syndrome	2.34e-06	6.02e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.34e-06	6.02e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—INS—polycystic ovary syndrome	2.33e-06	5.99e-06	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—IL6—polycystic ovary syndrome	2.32e-06	5.97e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—IL6—polycystic ovary syndrome	2.31e-06	5.94e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—IL6—polycystic ovary syndrome	2.29e-06	5.9e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.29e-06	5.89e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.25e-06	5.8e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—IL6—polycystic ovary syndrome	2.22e-06	5.73e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—GNAS—polycystic ovary syndrome	2.22e-06	5.71e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.17e-06	5.58e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.14e-06	5.51e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—IL6—polycystic ovary syndrome	2.12e-06	5.46e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—IL6—polycystic ovary syndrome	2.11e-06	5.44e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—NCOR1—polycystic ovary syndrome	2.11e-06	5.44e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—TH—polycystic ovary syndrome	2.09e-06	5.4e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—SLC2A4—polycystic ovary syndrome	2.04e-06	5.25e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—IL6—polycystic ovary syndrome	2e-06	5.17e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—CYP1A1—polycystic ovary syndrome	2e-06	5.15e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CYP19A1—polycystic ovary syndrome	1.92e-06	4.93e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PPARG—polycystic ovary syndrome	1.89e-06	4.88e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—IL6—polycystic ovary syndrome	1.89e-06	4.88e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.87e-06	4.83e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—POMC—polycystic ovary syndrome	1.87e-06	4.81e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—MTHFR—polycystic ovary syndrome	1.87e-06	4.81e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—INS—polycystic ovary syndrome	1.86e-06	4.79e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—IL6—polycystic ovary syndrome	1.85e-06	4.77e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—IL6—polycystic ovary syndrome	1.79e-06	4.62e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—IL6—polycystic ovary syndrome	1.77e-06	4.57e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GNAS—polycystic ovary syndrome	1.71e-06	4.4e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.66e-06	4.27e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—IL6—polycystic ovary syndrome	1.64e-06	4.22e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—NCOR1—polycystic ovary syndrome	1.63e-06	4.2e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—IL6—polycystic ovary syndrome	1.62e-06	4.16e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—IL6—polycystic ovary syndrome	1.58e-06	4.07e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—IL6—polycystic ovary syndrome	1.56e-06	4.01e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CYP1A1—polycystic ovary syndrome	1.54e-06	3.98e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PPARG—polycystic ovary syndrome	1.51e-06	3.9e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—IL6—polycystic ovary syndrome	1.5e-06	3.86e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—POMC—polycystic ovary syndrome	1.49e-06	3.84e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—INS—polycystic ovary syndrome	1.48e-06	3.82e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—IL6—polycystic ovary syndrome	1.48e-06	3.81e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—MTHFR—polycystic ovary syndrome	1.44e-06	3.71e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—IL6—polycystic ovary syndrome	1.3e-06	3.34e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PPARG—polycystic ovary syndrome	1.17e-06	3.01e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—POMC—polycystic ovary syndrome	1.15e-06	2.97e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IL6—polycystic ovary syndrome	1.15e-06	2.96e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—INS—polycystic ovary syndrome	1.14e-06	2.95e-06	CbGpPWpGaD
